drugset / Trial / NCT06696833
Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This clinical trial aims to investigate the safety, optimal dosage, and effectiveness of allogeneic CD19-targeted CAR-γδT Cell in treating CD19-positive relapsed/refractory B-ALL
Timeline
- Start
- 2024-12-01
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QH10304-BAL-01 | Cell therapy | 3e+08 cells/kg | Intravenous |
| Subject | QH10304-BAL-01 | Cell therapy | 1e+09 cells/kg | Intravenous |
| Subject | QH10304-BAL-01 | Cell therapy | 3e+09 cells/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 1000 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |